The
Both boards have unanimously approved the takeover, which will strengthen
The pair will target the addiction market in the US, where overdose deaths are at a near record high,
While the deal has secured a green light from the board, the transaction awaits the approval of shareholders, as well as clearance by US antitrust officials.
Opiant's overdose rescue treatment OPNT003, used for synthetic opioids such as fentanyl, is expected to have the potential for an annual net revenue of between
(c) 2022 City A.M., source